Feature|Videos|September 16, 2026

AI’s Impact on Pharma Leadership Strategies

Inizio's Elaine Ferguson on why AI value requires deconstructing workflows task by task — aligning each to the right combination of talent and technology.

It’s a time of evolution for pharma and biotech leaders. New technologies and changing regulatory landscapes are forcing them to adjust their strategies, especially in how they manage and grow their own teams.

Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in leadership positions to identify potential future-leaders and provide them with clear and direct paths up the career ladder.

As the executive sponsor for the company’s talent accelerator, she plays a key role in developing these pathways. According to her, this requires an understanding of the current system, along with the ability to reach potential leaders where they are already at.

Pharmaceutical Executive: What impact is AI having on pharma leadership?
Elaine Ferguson: We talk about AI across all of our business — both in terms of the opportunities it creates and the risks it introduces in how we deliver for clients. But we cannot unlock that value through technology alone. What is critical is combining our technology capabilities with our human expertise. At Inizio, we believe our uniqueness and our value depend on that combination — bringing together our experts and the advances in AI to create opportunities that neither could deliver independently.

One of the most important elements of how we apply this in practice is deconstructing our workflows. That means identifying the specific tasks within a workflow and then deliberately aligning each task to the right combination of talent and AI capability. By doing this across our global workforce, we can both understand where AI tools add the most value and augment our people's work in the areas where those tools are most effective.

This approach extends beyond project delivery. We are also applying AI and automation across our support functions. Most recently, we have seen meaningful success in transforming our finance operations — deploying automation in a way that brings greater sophistication and efficiency to how we support our employees and conduct our business more broadly.


Related to this article

Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
How QMM Can Help the C-Suite See a  $100 Million Problem Early
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Dr. Bo Liang
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.